AP
TEVA icon

Atwood & Palmer’s Teva Pharmaceuticals TEVA Stock Holding History

Atwood & Palmer’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$31.2K – 556
2025
Q4 		$31.2K Hold
1,000
– – ﹤0.01% 277
2025
Q3 		$20.2K Hold
1,000
– – ﹤0.01% 332
2025
Q2 		$16.8K Buy
+1,000
New +$16.1K ﹤0.01% 339
2016
Q4 		– Sell
-172
Closed -$8K – 337
2016
Q3 		$8K Hold
172
– – ﹤0.01% 271
2016
Q2 		$9K Hold
172
– – ﹤0.01% 258
2016
Q1 		$9K Sell
172
-139
-45% -$8.16K ﹤0.01% 259
2015
Q4 		$20K Hold
311
– – ﹤0.01% 272
2015
Q3 		$18K Hold
311
– – ﹤0.01% 278
2015
Q2 		$18K Buy
+311
New +$19.2K ﹤0.01% 258

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atwood & Palmer's TEVA Position: Q1 2026 in Review

Atwood & Palmer sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 1,000 shares — an estimated $31.2K sold.

Atwood & Palmer first reported a position in TEVA in Q2 2015 and held it in 9 quarters. The position peaked at $31.2K in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Atwood & Palmer reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Atwood & Palmer sold 1,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $31.2K.
  • Atwood & Palmer first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 9 quarters.
  • Atwood & Palmer's Teva Pharmaceuticals position peaked at $31.2K in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Atwood & Palmer's 13F filing for Q1 2026, filed 15 Apr 2026.